Navigation Links
Galderma Launches New Cetaphil(R) SPF 50 Product
Date:2/17/2009

Top Skin Care Brand is Taking Facial Sun Protection to a New Level

FORT WORTH, Texas, Feb. 17 /PRNewswire/ -- Galderma Laboratories is excited to introduce a NEW SPF 50 facial moisturizer from Cetaphil(R), the #1 dermatologist-recommended brand of cleansers and moisturizers, that provides broad spectrum protection. Finally, a product that goes beyond moisturizing, to provide the highest SPF available for a moisturizer designed specifically for the face. Cetaphil(R) UVA/UVB Defense SPF 50 is non-greasy; it nourishes and hydrates skin, while protecting it from the sun's harmful rays.

Cetaphil(R) UVA/UVB Defense SPF 50 delivers across the spectrum to help protect skin from UVA/UVB rays, and help hydrate as a daily facial moisturizer. It contains an optimum blend of 4 filters and micronized Titanium Dioxide that screen both the UVA and UVB rays. For patients requiring an effective sunscreen as part of the management of their skin related condition, Cetaphil(R) UVA/UVB Defense SPF 50 combines two steps in one making it an ideal choice for both daily sun protection and for moisturizing the face.

Cetaphil(R) UVA/UVB Defense SPF 50 has also been awarded the Skin Cancer Foundation Seal of Recommendation. The Skin Cancer Foundation recommends this product as an effective UV facial sunscreen and as an effective aid in the prevention of sun induced damage to the skin including sunburn and possibly, premature aging. It is important to use proper UVA/UVB filters to help prevent sunburn and other skin damage.

The lightweight formula of the Cetaphil(R) UVA/UVB Defense SPF 50 hydrates the skin to avoid evaporation and absorbs quickly, leaving no filmy white residue. It is fragrance free, non-irritating and non-comedogenic, so it won't clog pores, making it a suitable choice for those with acne, rosacea or melasma and other skin related conditions, where a hydrating formula with SPF protection is recommended.

Cetaphil(R) UVA/UVB Defense SPF 50 is available in a 1.7 oz. tube for $13.99 and is available at major retail, grocery and drug stores nationwide.

For more information about Cetaphil(R) products or to join the Cetaphil(R) Skin Care Club, visit www.cetaphil.com.

About Galderma

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully-integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company is committed to improving the health of skin with an extensive line of products across the world that treat a range of dermatological conditions. With a research and development center in Sophia Antipolis, France, Galderma has one of the largest R&D facilities dedicated exclusively to dermatology. Leading worldwide dermatology brands include Differin(R), MetroGel(R) 1%/Rozex(R), Clobex(R), Tri-Luma(R), Loceryl(R) and Cetaphil(R).

For more information on Galderma, visit www.galdermaUSA.com.

About Cetaphil

The Family of Cetaphil(R) Cleansers and Moisturizers is a line of dermatologist-recommended skin care products specially formulated for all skin types and conditions. Cetaphil(R) products are developed to provide effective, gentle skin care and include: Cetaphil(R) Gentle Skin Cleanser, Cetaphil(R) Daily Facial Cleanser, Cetaphil(R) Gentle Cleansing Bar, Cetaphil(R) Antibacterial Gentle Cleansing Bar, Cetaphil(R) Moisturizing Lotion, Cetaphil(R) Moisturizing Cream, Cetaphil(R) DailyAdvance Ultra Hydrating Lotion, Cetaphil(R) Daily Facial Moisturizer SPF 15, Cetaphil(R) Therapeutic Hand Cream.

To learn more about Cetaphil(R) products and to join the Cetaphil(R) Skin Care Club visit www.cetaphil.com


'/>"/>
SOURCE Galderma Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
2. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
3. Galderma announces approval for Differin gel 0.1 percent in Japan
4. Galderma Completes Tender Offer for CollaGenex
5. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
6. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
7. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
8. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
9. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
10. Crossover Health Launches Personal Health Advisory Service
11. Photos: Medpedia Launches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came ... contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand ... recently invested $51 million to purchase and renovate the 185,000 square-foot office complex, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to fewer trips the emergency room, fewer hospital admissions, and better blood pressure ... Managed Care® (AJMC®) finds. The study can be found here . , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... 23, 2017 MabVax Therapeutics Holdings, ... development company, announces that it has received notice ... authorizing the initiation a Phase I clinical trial ... cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s ... to initiate the phase I clinical trial in ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: